Robert W. Baird analyst Brian Skorney maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) on January 9 and set a price target of $152.00. The company’s shares closed yesterday at $120.13.
According to TipRanks, Skorney is an analyst with an average return of -4.2% and a 44.20% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Biogen, Sarepta Therapeutics, and Applied Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $148.88 average price target, which is a 23.93% upside from current levels. In a report released on January 10, Cowen & Co. also maintained a Buy rating on the stock with a $125.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
SRPT market cap is currently $10.46B and has a P/E ratio of -14.51.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is neutral on the stock. Last month, Kathleen Behrens, a Director at SRPT bought 20,000.00 shares for a total of $698,400.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Read More on SRPT:
- UBS Says These 2 Stocks Offer Attractive Risk-Reward Right Now — Here’s Why
- Sarepta price target raised to $160 from $158 at Needham
- Sarepta price target raised to $114 from $101 at Credit Suisse
- Sarepta expects to exceed FY22 guidance for net product revenues
- Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues